1968P Study EV-103 Dose Escalation/cohort A (DE/A): 5y Follow-Up of First-Line (1L) Enfortumab Vedotin (EV) + Pembrolizumab (P) in Cisplatin (Cis)-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (La/muc)
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined